Equities research analysts expect Cambrex Co. (NYSE:CBM) to announce sales of $163.21 million for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Cambrex’s earnings. The highest sales estimate is $164.91 million and the lowest is $161.79 million. Cambrex posted sales of $152.05 million in the same quarter last year, which suggests a positive year-over-year growth rate of 7.3%. The firm is scheduled to announce its next earnings results on Thursday, August 1st.
According to Zacks, analysts expect that Cambrex will report full year sales of $645.25 million for the current fiscal year, with estimates ranging from $641.75 million to $647.38 million. For the next financial year, analysts forecast that the firm will post sales of $659.09 million, with estimates ranging from $656.71 million to $662.96 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Cambrex.
Cambrex (NYSE:CBM) last released its earnings results on Thursday, May 2nd. The biotechnology company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.10. The company had revenue of $159.46 million during the quarter, compared to analyst estimates of $159.71 million. Cambrex had a return on equity of 12.25% and a net margin of 14.35%. Cambrex’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.72 EPS.
A number of research firms have commented on CBM. Craig Hallum lowered their price target on Cambrex from $71.00 to $45.00 and set a “buy” rating for the company in a research report on Thursday, February 14th. First Analysis lowered Cambrex from a “strong-buy” rating to an “outperform” rating and upped their price target for the company from $45.00 to $55.00 in a research report on Tuesday, May 7th. Robert W. Baird lowered Cambrex from an “outperform” rating to a “neutral” rating and set a $44.00 price target for the company. in a research report on Friday, May 3rd. They noted that the move was a valuation call. Zacks Investment Research raised Cambrex from a “hold” rating to a “strong-buy” rating and set a $52.00 price target for the company in a research report on Friday, May 10th. Finally, ValuEngine raised Cambrex from a “strong sell” rating to a “sell” rating in a research report on Friday, February 22nd. Two equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Cambrex presently has an average rating of “Buy” and a consensus price target of $47.80.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Marshall Wace LLP purchased a new position in shares of Cambrex during the 1st quarter worth approximately $30,000. Enlightenment Research LLC purchased a new position in shares of Cambrex during the 4th quarter worth approximately $30,000. Flagship Harbor Advisors LLC grew its holdings in shares of Cambrex by 2,725.8% during the 1st quarter. Flagship Harbor Advisors LLC now owns 876 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 845 shares during the period. Private Capital Group LLC grew its holdings in shares of Cambrex by 31.6% during the 1st quarter. Private Capital Group LLC now owns 1,978 shares of the biotechnology company’s stock worth $77,000 after acquiring an additional 475 shares during the period. Finally, NumerixS Investment Technologies Inc purchased a new position in shares of Cambrex during the 4th quarter worth approximately $79,000.
CBM opened at $43.67 on Thursday. The company has a market cap of $1.44 billion, a price-to-earnings ratio of 15.77, a price-to-earnings-growth ratio of 3.33 and a beta of 2.32. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.96 and a quick ratio of 2.01. Cambrex has a one year low of $33.80 and a one year high of $69.43.
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.
Featured Story: The role of implied volatility with call option volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.